Aquestive Historical Income Statement
| AQST Stock | USD 5.16 0.28 5.74% |
Historical analysis of Aquestive Therapeutics income statement accounts such as Selling General Administrative of 43.5 M, Total Revenue of 48.2 M or Gross Profit of 31.9 M can show how well Aquestive Therapeutics performed in making a profits. Evaluating Aquestive Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Aquestive Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Aquestive Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aquestive Therapeutics is a good buy for the upcoming year.
Aquestive |
About Aquestive Income Statement Analysis
Aquestive Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Aquestive Therapeutics shareholders. The income statement also shows Aquestive investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Aquestive Therapeutics Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Aquestive Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Aquestive Therapeutics minus its cost of goods sold. It is profit before Aquestive Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Most accounts from Aquestive Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Aquestive Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aquestive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more information on how to buy Aquestive Stock please use our How to Invest in Aquestive Therapeutics guide.At this time, Aquestive Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 92.3 M in 2024, whereas Net Loss is likely to drop (8.3 M) in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 35.8M | 28.3M | 29.8M | 31.9M | Total Revenue | 50.8M | 47.7M | 50.6M | 48.2M |
Aquestive Therapeutics income statement Correlations
Click cells to compare fundamentals
Aquestive Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aquestive Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 9.3M | 13.0M | 22.5M | 12.4M | 7.5M | 9.5M | |
| Selling General Administrative | 64.3M | 55.9M | 53.5M | 52.9M | 31.8M | 43.5M | |
| Total Revenue | 52.6M | 45.8M | 50.8M | 47.7M | 50.6M | 48.2M | |
| Gross Profit | 32.2M | 32.9M | 35.8M | 28.3M | 29.8M | 31.9M | |
| Operating Income | (52.7M) | (42.9M) | (34.7M) | (42.1M) | (15.1M) | (15.9M) | |
| Net Income From Continuing Ops | (66.2M) | (55.8M) | (70.5M) | (54.4M) | (7.9M) | (8.3M) | |
| Ebit | (52.7M) | (42.8M) | (48.1M) | (42.0M) | (163K) | (171.2K) | |
| Research Development | 20.6M | 19.9M | 17.0M | 17.5M | 13.1M | 16.7M | |
| Cost Of Revenue | 20.4M | 13.0M | 15.0M | 19.4M | 20.8M | 16.3M | |
| Total Operating Expenses | 84.9M | 75.8M | 70.5M | 70.4M | 44.9M | 60.5M | |
| Income Before Tax | (66.2M) | (55.8M) | (70.5M) | (54.4M) | (7.6M) | (8.0M) | |
| Total Other Income Expense Net | (13.6M) | (12.9M) | (35.9M) | (12.3M) | 7.5M | 7.9M | |
| Net Income Applicable To Common Shares | (66.2M) | (55.8M) | (70.5M) | (54.4M) | (49.0M) | (51.4M) | |
| Net Income | (72.7M) | (65.4M) | (90.0M) | (60.2M) | (7.9M) | (8.3M) | |
| Income Tax Expense | 6.4M | 9.6M | 19.5M | 5.8M | 245K | 232.8K | |
| Interest Income | 636K | 132K | 423K | 99K | 16.3M | 17.1M | |
| Net Interest Income | (8.7M) | (12.9M) | (22.0M) | (12.3M) | 8.9M | 9.3M | |
| Depreciation And Amortization | 636K | 3.6M | 3.0M | 2.4M | 1.3M | 2.2M | |
| Other Operating Expenses | 105.3M | 88.7M | 85.5M | 89.7M | 65.7M | 92.3M | |
| Ebitda | (52.0M) | (39.2M) | (45.1M) | (39.6M) | 1.2M | 1.2M | |
| Reconciled Depreciation | 2.9M | 3.4M | 3.0M | 2.4M | 1.3M | 2.3M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aquestive Stock Analysis
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.